(Q34363276)

1 August 2017

title

Current place of monoamine oxidase inhibitors in the treatment of depression (English)

1 reference

1 August 2017

Kenneth I Shulman

1

1 reference

1 August 2017

Nathan Herrmann

series ordinal

2

1 reference

1 August 2017

Scott E Walker

series ordinal

3

1 reference

1 August 2017

publication date

1 October 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

27

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

789-797

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-013-0097-3

1 August 2017

exact match

0 references

cites work

Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Regulation of MAO-A and MAO-B gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Monoamine oxidase (MAO) in human peripheral tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Localization of monoamine oxidases A and B in primate brains relative to neuron-specific and non-neuronal enolases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Selective inhibitors of monoamine oxidase type B and the "cheese effect".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

MAO inhibitors: risks, benefits, and lore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Severe adverse interaction between pethidine and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Interactions between sympathomimetic amines and antidepressant agents in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Ageing, monoamines, and monoamine-oxidase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Atypical depression: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Treatment of depression with atypical features: a meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Prediction of longer-term outcome of treatment-resistant depression in tertiary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Deep brain stimulation for psychiatric disease: contributions and validity of animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

An algorithm for the pharmacological treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Clinical pharmacology of MAO inhibitors: safety and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Seligiline transdermal system in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Moclobemide and fluoxetine in atypical depression: a double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Monoamine oxidase inhibitors revisited: what you should know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0097-3

A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.

21 January 2018

1 reference

12 December 2020

Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor

1 reference

12 December 2020

Diet and monoamine oxidase inhibitors: a re-examination

1 reference

12 December 2020

Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo

1 reference

12 December 2020

Treating depression with atypical features

1 reference

12 December 2020

The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.

1 reference

12 December 2020

Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group

1 reference

12 December 2020

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

1 reference

12 December 2020

Depression with anxiety and atypical depression

1 reference

12 December 2020

MAOIs in the contemporary treatment of depression

1 reference

12 December 2020

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

1 reference

12 December 2020

Tyramine pressor sensitivity changes during deprenyl treatment

1 reference

12 December 2020

Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo

1 reference

12 December 2020

Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers

1 reference

12 December 2020

Results of the STAR*D study: implications for clinicians and drug developers

1 reference

12 December 2020

Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies?

1 reference

12 December 2020

Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study

1 reference

12 December 2020

Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors

1 reference

12 December 2020

HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS

1 reference

12 December 2020

Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors

1 reference

12 December 2020

A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients

1 reference

12 December 2020

Revisiting monoamine oxidase inhibitors.

1 reference

12 December 2020

Why aren't MAOIs used more often?

1 reference

12 December 2020

Treatment with low doses of tranylcypromine resulted in a disappointing remission rate

1 reference

12 December 2020

Fluoxetine: clinical pharmacology and physiologic disposition

1 reference

12 December 2020

10.1007/S40263-013-0097-3

Identifiers

DOI

1 reference

1 August 2017

1 reference